Know Cancer

forgot password

Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib

Phase 2
18 Years
Not Enrolling
Relapse Multiple Myeloma, Refractory Multiple Myeloma

Thank you

Trial Information

Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib

This is an open label, single center, phase II study of high dose carfilzomib. Patients with
relapsed or relapsed/refractory myeloma and with progression of disease on standard dosing
(20/27 mg/m2) and schedule of carfilzomib will be initially treated at dose level 1,
carfilzomib 20/56 mg/m2. During Cycle 1, patients will receive either 20 mg/m2 on days 1,2
(if the subject has not received carfilzomib as part another clinical trial within the last
4 weeks) or 56 mg/m2 (if the subject is enrolling in the present study after progression of
disease on carfilzomib within the last month - for example subjects enrolled in CMAP
compassionate use carfilzomib). Thereafter, all subjects will receive 56 mg/m2 for the
remaining doses given Cycle 1 Day 8 onwards. If a minimal response or better is achieved
(and therefore disease response is recaptured) a bone marrow biopsy will be repeated.

If 56 mg/m2 is not tolerated, the dose of carfilzomib will be reduced to dose level -1 i.e.
45 mg/m2. If a subject does not tolerate 45 mg/m2 then the dose would be further reduced to
dose level -2 i.e. 36 mg/m2. If the subject does not tolerate 36 mg/m2, then this subject
would have to come off study.

Dexamethasone 8 mg po/IV will be administered prior to all carfilzomib doses.

Once a patient develops disease progression on this study, the patient may return to
receiving the maximum tolerated dose of carfilzomib by that patient with the addition of a
therapeutic dosing of dexamethasone (a total of 20-40 mg weekly). An IMId (e.g. thalidomide
or lenalidomide) and/or an alkylator can also be added to carfilzomib 27 or 36 mg/m2 per
investigator discretion either concurrent with the addition of dexamethasone or subsequent
to disease progression on carfilzomib with concurrent therapeutic dexamethasone.

Inclusion Criteria:


1. Multiple myeloma

2. Subjects must have measurable disease, defined as one or both of the following:

1. Serum M-protein ≥ 1.0 g/dL

2. Urine M-protein ≥ 200 mg/24 hours

3. Free light chains: Only in patients without measureable serum and urine
M-protein levels: the difference between involved and uninvolved FLC levels must
be at least 10 mg/dl.

3. Refractory to the most recently received therapy. Refractory disease is defined as ≤
25% response or progression during therapy or within 60 days after completion of

4. Subjects must have progressed on standard dose 20/27 mg/m2 and schedule of
carfilzomib without having had any carfilzomib related grade 3 or 4 toxicities.

5. Subjects must have received ≥ 2 prior regimens for relapsed disease. Induction
therapy and stem cell transplant will be considered as one regimen

6. Subjects must have received prior treatment with bortezomib, and either thalidomide
or lenalidomide

7. Subjects must have received an alkylating agent unless contraindicated. Subjects may
have received these agents alone or in combination with other myeloma treatments.


1. Age ≥ 18 years

2. Life expectancy ≥ 3 months

3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2


1. Adequate hepatic function, with serum ALT ≤ 3.5 times the upper limit of normal and
serum direct bilirubin ≤ 2 mg/dL (34 µmol/L) within 14 days prior to randomization

2. Uric acid, if elevated, must be corrected to within laboratory normal range prior to

3. Absolute neutrophil count (ANC) ≥ 1.0 × 109/L within 14 days prior to randomization
independent of G-CSF for ≥ 1 week and pegylated G-CSF for ≥ 2 weeks

4. Hemoglobin ≥ 8 g/dL (80 g/L) within 14 days prior to randomization (subjects may be
receiving red blood cell [RBC] transfusions in accordance with institutional

5. Screening platelet count ≥ 50 × 109/L independent of platelet transfusions for at
least 2 weeks

6. Creatinine clearance (CrCl) ≥ 15 mL/minute within 7 days prior to randomization,
either measured or calculated using a standard formula (eg, Cockcroft and Gault)

7. LVEF ≥ 40% within 30 days before Cycle 1 Day 1. 2-D Transthoracic Echocardiogram
(ECHO) is the preferred method of evaluation; MUGA is acceptable if ECHO is not

Exclusion Criteria:


1. Glucocorticoid therapy (prednisone > 10 mg/day or equivalent) within the last three

2. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and
skin changes)

3. Chemotherapy with approved or investigative anticancer therapeutics including steroid
therapy within the three weeks prior to first dose (unless enrolling on this study
after progression CMAP compassionate use carfilzomib protocol, in which case subject
may proceed with current study treatment on next expected date of treatment)

4. Radiation therapy or immunotherapy in the previous four weeks; localized radiation
therapy within 1 week prior to first dose

5. Participation in an investigational therapeutic study within three weeks or within
five drug half-lives (t1/2) prior to first dose, whichever time is greater (unless
enrolling after progression on CMAP compassionate use carfilzomib protocol)

Concurrent Conditions

1. Pregnant or lactating females

2. Major surgery within 21 days prior to randomization

3. Acute active infection requiring treatment (systemic antibiotics, antivirals, or
antifungals) within 14 days prior to randomization

4. Known human immunodeficiency virus infection

5. Known active hepatitis B or C infection

6. Unstable angina or myocardial infarction within 4 months prior to randomization, NYHA
Class III or IV heart failure, uncontrolled angina, history of severe coronary artery
disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or
electrocardiographic evidence of acute ischemia or Grade 3 conduction system
abnormalities unless subject has a pacemaker

7. Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to

8. Nonhematologic malignancy within the past 3 years with the exception of a) adequately
treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b)
carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or
less with stable prostate-specific antigen levels; or d) cancer considered cured by
surgical resection or unlikely to impact survival during the duration of the study,
such as localized transitional cell carcinoma of the bladder or benign tumors of the
adrenal or pancreas

9. Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to

10. Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize

11. Contraindication to any of the required concomitant drugs or supportive treatments,
including antiviral drugs, or intolerance to hydration due to preexisting pulmonary
or cardiac impairment

12. Subjects with pleural effusions requiring thoracentesis or ascites requiring
paracentesis within 14 days prior to randomization

13. Any other clinically significant medical disease or condition that, in the
Investigator's opinion, may interfere with protocol adherence or a subject's ability
to give informed consent

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety and Efficacy of High Dose Carfilzomib

Outcome Description:

To explore the safety and efficacy of high dose carfilzomib who developed disease progression on the standard dosing and schedule of carfilzomib

Outcome Time Frame:

up to 4 years

Safety Issue:


Principal Investigator

Ajai Chari, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Mount Sinai School of Medicine


United States: Food and Drug Administration

Study ID:

GCO 12-1506



Start Date:

February 2013

Completion Date:

August 2016

Related Keywords:

  • Relapse Multiple Myeloma
  • Refractory Multiple Myeloma
  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma
  • High-Dose Carfilzomib
  • Standard Dose Carfilzomib
  • Carfilzomib
  • Multiple Myeloma
  • Neoplasms, Plasma Cell



Mount Sinai Medical Center New York, New York  10029